Better is always possible.
Our Mission
At Frenelle Pharma we adapt and create. We think big about the small. We challenge ourselves to improve what already exists, and we refuse to accept “good enough”.
Our Mission
At Frenelle Pharma we adapt and create. We think big about the small. We challenge ourselves to improve what already exists, and we refuse to accept “good enough”.
About
Frenelle Pharma has invested decades in perfecting its innovative long-acting injectable (LAI) drug delivery technology, Faros™, and we are poised to both disrupt markets and impact patients’ lives. We are using our Faros™ technology to deliver powerful solutions across multiple therapeutic areas.
About
Frenelle Pharma has invested decades in perfecting its innovative long-acting injectable (LAI) drug delivery technology, Faros™, and we are poised to both disrupt markets and impact patients’ lives. We are using our Faros™ technology to deliver powerful solutions across multiple therapeutic areas.
.jpg)
Frenelle Pharma has successfully launched three companies built on our Faros™
technology, each focused on a therapeutic area: SpineThera, a Phase 2 therapeutic
company advancing SX600 for the potential to transform treatment of lumbar radicular
pain (sciatica); Frenelle PBC, a collaboration with the Mayo Clinic to develop long-acting
injectables for substance use disorders with a mission to maximize access and
utilization; and Anumio, an animal health company focused long-acting injectable drugs for companion animals approvable via the FDA’s Expanded Conditional Approval
pathway to rapidly advance to commercialization.
Anumio
Stage 1
Stage 2
Stage 3
Stage 4
Frenelle PBC
SpineThera
awdawd_edited.jpg)
The Frenelle Pharma systematic approach drives success from discovery to commercialization:
Stage 1 - Identification and selection of new opportunities
Stage 2 - Pre-clinical evaluation to demonstrate key product performance attributes
Stage 3 – Proof of concept clinical trial to determine a go/no-go decision
Stage 4 – Pivotal studies to enable regulatory approval and product launch
We welcome inquiries about direct investment in our subsidiaries as well as co-
development and out-licensing opportunities for the Faros™ technology.
Frenelle Pharma has successfully launched three companies built on our Faros™ technology, each focused on a therapeutic area: SpineThera, a Phase 2 therapeutic company advancing SX600 for the potential to transform treatment of lumbar radicular pain (sciatica); Frenelle PBC, a collaboration with the Mayo Clinic to develop long-acting injectables for substance use disorders with a mission to maximize access and utilization; and Anumio, an animal health company focused long-acting injectable drugs for companion animals approvable via the FDA’s Expanded Conditional Approval pathway to rapidly advance to commercialization.
Anumio
Stage 1
Stage 2
Stage 3
Stage 4
Frenelle PBC
SpineThera
The Frenelle Pharma systematic approach drives success from discovery to commercialization:
Stage 1 - Identification and selection of new opportunities
Stage 2 - Pre-clinical evaluation to demonstrate key product performance attributes
Stage 3 – Proof of concept clinical trial to determine a go/no-go decision
Stage 4 – Pivotal studies to enable regulatory approval and product launch
We welcome inquiries about direct investment in our subsidiaries as well as co-
development and out-licensing opportunities for the Faros™ technology.
Frenelle Pharma has successfully launched three companies built on our Faros™ technology, each focused on a therapeutic area: SpineThera, a Phase 2 therapeutic company advancing SX600 for the potential to transform treatment of lumbar radicular pain (sciatica); Frenelle PBC, a collaboration with the Mayo Clinic to develop long-acting injectables for substance use disorders with a mission to maximize access and utilization; and Anumio, an animal health company focused on long-acting injectable drugs for companion animals approvable via the FDA’s Expanded Conditional Approval pathway to rapidly advance to commercialization.
Anumio
Frenelle PBC
SpineThera
Stage 4
Stage 3
Stage 2
Stage 1
The Frenelle Pharma systematic approach drives success from discovery to commercialization:
Stage 1 - Identification and selection of new opportunities
Stage 2 - Pre-clinical evaluation to demonstrate key product performance attributes
Stage 3 – Proof of concept clinical trial to determine a go/no-go decision
Stage 4 – Pivotal studies to enable regulatory approval and product launch
We welcome inquiries about direct investment in our subsidiaries as well as co-development and out-licensing opportunities for the Faros™ technology.
Our Business Model
Our Technology
Frenelle’s innovative long-acting injectable (LAI) drug delivery technology, Faros™, has demonstrated traction across three disparate areas of high unmet need – back pain, substance use disorders, and animal health. The Faros™ technology has been proven in several animal models and a phase 2 clinical study. Looking beyond LAIs, the Frenelle team is exploring additional applications of the Faros platform, including inhalation.
Our Technology
Frenelle’s innovative long-acting injectable (LAI) drug delivery technology, Faros™, has demonstrated traction across three disparate areas of high unmet need – back pain, substance use disorders, and animal health. The Faros™ technology has been proven in several animal models and a phase 2 clinical study. Looking beyond LAIs, the Frenelle team is exploring additional applications of the Faros platform, including inhalation.
